McKesson’s 2024 Cell and Gene Therapy (CGT) Report outlines the evolving landscape of CGT, where life-changing therapies are no longer a distant vision but a clinical reality.
The report examines where the CGT industry stands today, capturing both the breakthroughs and the barriers to widespread patient access.
Our CEO Jason C. Foster was one of the experts who shared their perspectives on the state of the CGT industry and its future trajectory.
“As an industry we need to focus on product viability, alongside safety and efficacy early in pre-clinical development, to ensure these incredible products are able to make it to all patients who need them.” – Jason C. Foster
We’ve summarized the key takeaways from the report…
1. Oncology dominates the CGT pipeline
There are 734 unique CGTs in development. Whilst oncology is the largest area of development, broader indications could expand in the years to come.
2. Barriers to scalable development
Despite its promise, CGTs face many barriers to commercial development like high costs and manufacturing complexity. Patient access also remains limited, especially in rural regions.
“Three out of five doctors say the patients they refer for CGTs often receive other therapies. They cite insurance coverage and patient out-of-pocket costs as the top reasons.”
3. Payment models
New value-based payment models are essential for CGTs, given that the estimated benchmark of two recently approved gene therapies for sickle cell disease ranged from $1.35m – $2.05m health benefit price.
4. The geography of CGT access
Over 60 million Americans in rural areas face limited access to CGT centers, as most are concentrated in urban, academic medical hubs. Patients living 2-4 hours from a CGT center are 40% less likely to receive therapy.
Download the full report.